SCHEMBL24619217

SCHEMBL24619217

CC(C)(C)OC(=O)NCc1ccc(B2OC(C)(C)C(C)(C)O2)c(C(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
AAK1 Q2M2I8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
GRM2 Q14416 1/20 0.38
NAMPT P43490 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
HDAC1 Q13547 1/20 0.36
GAA P10253 1/20 0.35
KDM4A O75164 1/20 0.35
GLS O94925 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29925213 0.86 PRMT5 (0.48) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL20095411 0.86 PRMT5 (0.48) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL30954635 0.84 PRMT5 (0.48) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL29924642 0.84 PRMT5 (0.48) PRMT5WDR77AAK1L3MBTL1NAMPT
SCHEMBL24619251 0.84 PRMT5 (0.48) PRMT5WDR77AAK1L3MBTL1NAMPT
SCHEMBL31694714 0.81 PRMT5 (0.46) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL30954637 0.80 PRMT5 (0.45) PRMT5WDR77AAK1L3MBTL1NAMPT
SCHEMBL24619901 0.80 PRMT5 (0.45) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL29924784 0.80 PRMT5 (0.45) PRMT5WDR77AAK1L3MBTL1GRM2
SCHEMBL22409228 0.79 PRMT5 (0.44) PRMT5WDR77AAK1L3MBTL1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 EP disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 CN disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 PRMT5 720/4885WDR77 561/4885AAK1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.